Business
Recursion and Bayer Expand Fibrosis Collaboration to Include Inferential Search Capabilities
Use of latest Recursion inference technologies to expand exploration of fibrosis and may extend the collaboration to more than a dozen programs in total
About this update from Recursion Pharmaceuticals, Inc.
[{"type":"text","content":"Use of latest Recursion inference technologies to expand exploration of fibrosis and may extend the collaboration to more than a dozen programs in total\n Recursion's powerful inferential search capabilities leverage more than 100 million prior experiments conducted in Recursion's automated laboratory to infer hundreds of billions of biological relationships\n Map-based approach will further accelerate and drive greater efficiencies in drug discovery\n\n\nSALT LAKE CITY, Dec. 6, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, today announced expansion of the company's existing strategic collaboration in fibrosis with Bayer AG. The expanded collaboration will include Recursion's powerful inferential search capabilities based on its growing maps of human cellular biology, giving Bayer the ability to further accelerate the work already underway in expanding the universe of novel fibrotic hypotheses. Recursion and Bayer may now work on more than a dozen programs in total of relevance to fibrotic disease. All projects will remain subject to the previously agreed upon economics, where each potential program could generate more than $100 million in commercial milestone payments plus royalties on future sales.\n\n \n \n \n \n \n \n\n \nInferential search enables Recursion to materially expand the depth and breadth of the drug discovery space in a more efficient fashion – reducing time and costs to better operationalize the process. In the expanded collaboration, the company will leverage the Recursion Map, a collection of actionable scientific insights derived from the application of machine learning solutions on massive relatable datasets, to explore hundreds of billions of biological relationships that span whole-genome genetic perturbations, hundreds of soluble factors, and hundreds of thousands of pharmacological perturbations. Inferred relationships of interest will be validated in Recursion's wet-labs and digital vivariums to rapidly advance therapeutic hypotheses and generate data which is fed back into Recursion's Operating System to improve future predictions.\n\"Our collaborations are centered around the goal of delivering better drugs to patients faster than...